Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
Completed · Phase 1/Phase 2
Conditions studied: Pancreatic Neoplasms
In brief
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of pancreatic cancer.
Key facts
- Study ID
- NCT00041639
- Run by
- Gilead Sciences
- People needed
- 75
- Starts
- 2000-01-01
- Expected to finish
- 2003-12-01
- Last updated by the study team
- 2021-08-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hoag Cancer Center — Newport Beach, California, United States
- Washington Hospital Center — Washington D.C., District of Columbia, United States
- Bay Pines VA Medical Center — St. Petersburg, Florida, United States
- University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
- Virginia Mason Medical Center — Seattle, Washington, United States
- Medizinische Fakultaet der Charité Berlin — Berlin, Germany
- Universitaetsklinikum Leipzig — Leipzig, Germany
- Semmelweis University — Budapest, Hungary
- Medical University of Szeged — Szeged, Hungary
- Academic Medical Center — Amsterdam, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.